Olpasiran Expanded Access Program

Status

AVAILABLE

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT07079267

Enrollment

Unknown

Registered

2025-07-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Expanded access requests for Olpasiran may be considered for adult participants with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD). To request access, use Responsible Party contact information provided in this record.

Interventions

Sponsors

Amgen

Lead SponsorINDUSTRY

Eligibility

Age

18 Years to No maximum

Inclusion criteria

\-

Exclusion criteria

\-

Contacts

Primary ContactAmgen Call Center

medinfo@amgen.com866-572-6436

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026